Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
A phase 2 trial of Bevacizumab, Cemiplimab, Fianlimab in ovarian cancer, run by Regeneron Pharmaceuticals, now recruiting.
Overview
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer is a phase 2 interventional study registered as NCT06787612 by Regeneron Pharmaceuticals, with 297 participants planned, started 2025-05-28 and due to reach its primary completion in 2028-06-30. Interventions recorded: Ubamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD. Conditions listed: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamata
Shares Ubamatamab, Cemiplimab, Regeneron, Ovarian cancer.
- TrialStudy of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent
Shares Ubamatamab, Cemiplimab, Regeneron, Ovarian cancer.
- TrialA Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Shares Fianlimab, Cemiplimab, Regeneron.
- TrialA Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous
Shares Fianlimab, Cemiplimab, Regeneron.
- TrialA Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small
Shares Fianlimab, Cemiplimab, Regeneron.
- TrialA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back Af
Shares Fianlimab, Cemiplimab, Regeneron.
- TrialNeoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Shares Fianlimab, Cemiplimab, Regeneron.
- TrialA Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Shares Fianlimab, Cemiplimab, Regeneron.